These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30186483)

  • 1. Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials.
    Wu ZP; Zhang P; Bai JZ; Liang Y; He JS; Wang JC
    Exp Ther Med; 2018 Sep; 16(3):2449-2459. PubMed ID: 30186483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
    Dougados M; van der Heijde D; Chen YC; Greenwald M; Drescher E; Liu J; Beattie S; Witt S; de la Torre I; Gaich C; Rooney T; Schlichting D; de Bono S; Emery P
    Ann Rheum Dis; 2017 Jan; 76(1):88-95. PubMed ID: 27689735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials.
    Cai W; Tong R; Sun Y; Yao Y; Zhang J
    Front Pharmacol; 2024; 15():1387585. PubMed ID: 38725657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Z Rheumatol; 2018 May; 77(4):335-342. PubMed ID: 28097393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
    Tanaka Y; Atsumi T; Amano K; Harigai M; Ishii T; Kawaguchi O; Rooney TP; Akashi N; Takeuchi T
    Mod Rheumatol; 2018 Jul; 28(4):583-591. PubMed ID: 29134891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.
    Kremer JM; Schiff M; Muram D; Zhong J; Alam J; Genovese MC
    RMD Open; 2018; 4(1):e000581. PubMed ID: 29479473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
    Fleischmann R; Schiff M; van der Heijde D; Ramos-Remus C; Spindler A; Stanislav M; Zerbini CA; Gurbuz S; Dickson C; de Bono S; Schlichting D; Beattie S; Kuo WL; Rooney T; Macias W; Takeuchi T
    Arthritis Rheumatol; 2017 Mar; 69(3):506-517. PubMed ID: 27723271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
    Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
    J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Collins CE; Constantinescu F
    Clin Rheumatol; 2018 Oct; 37(10):2611-2620. PubMed ID: 30006916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE.
    Yang Y; Li XF; Zhang X; Bao CD; Hu JK; Xu JH; Li XP; Xu J; He DY; Li ZJ; Wang GC; Wu HJ; Ji F; Zhan LJ; Zerbini CAF; Li ZG
    Rheumatol Ther; 2020 Dec; 7(4):851-866. PubMed ID: 32876903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis.
    Weng C; Xue L; Wang Q; Lu W; Xu J; Liu Z
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X21999564. PubMed ID: 33815570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
    Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
    Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.
    Li Z; Hu J; Bao C; Li X; Li X; Xu J; Spindler AJ; Zhang X; Xu J; He D; Li Z; Wang G; Yang Y; Wu H; Ji F; Tao H; Zhan L; Bai F; Rooney TP; Zerbini CAF
    Clin Exp Rheumatol; 2020; 38(4):732-741. PubMed ID: 32452344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
    Keystone EC; Taylor PC; Drescher E; Schlichting DE; Beattie SD; Berclaz PY; Lee CH; Fidelus-Gort RK; Luchi ME; Rooney TP; Macias WL; Genovese MC
    Ann Rheum Dis; 2015 Feb; 74(2):333-40. PubMed ID: 25431052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
    Smolen JS; Kremer JM; Gaich CL; DeLozier AM; Schlichting DE; Xie L; Stoykov I; Rooney T; Bird P; Sánchez Bursón JM; Genovese MC; Combe B
    Ann Rheum Dis; 2017 Apr; 76(4):694-700. PubMed ID: 27799159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
    Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS
    N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.
    Wells AF; Greenwald M; Bradley JD; Alam J; Arora V; Kartman CE
    Rheumatol Ther; 2018 Jun; 5(1):43-55. PubMed ID: 29680881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids.
    van Vollenhoven R; Helt C; Arora V; Zhong J; Correia AP; de la Torre I; Muram D
    Rheumatol Ther; 2018 Dec; 5(2):525-536. PubMed ID: 30357613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.